Syngene COO On Delivering Cost Gains For mRNA Products
How CDMOs are Adapting to New mRNA Tech Demands
Why Indian Pharma Must Evolve As Value Creator
CRAMS underpinned by strong technical expertise
Orphan drug development remains a specialised segment with limited players
A Shifting Landscape – The outsourcing model is here to stay
Demand strong for R&D_mfg services says Syngene COO
Driven by big pharma needs, Syngene to focus on expanding breadth of services & capabilities
Seeing Good Demand for Chemistry, Biology
Syngene interview in 2022 edition of USA Life Sciences report